Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1021/acs.jpclett.0c01894

http://scihub22266oqcxt.onion/10.1021/acs.jpclett.0c01894
suck pdf from google scholar
32787337!7441750!32787337
unlimited free pdf from europmc32787337    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid32787337
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2 #MMPMID32787337
  • Gao J; Zhang L; Liu X; Li F; Ma R; Zhu Z; Zhang J; Wu J; Shi Y; Pan Y; Ge Y; Ruan K
  • J Phys Chem Lett 2020[Sep]; 11 (17): 7267-7272 PMID32787337show ga
  • The coronavirus disease pandemic caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global healthcare system. As low-molecular-weight drugs have high potential to completely match interactions with essential SARS-CoV-2 targets, we propose a strategy to identify such drugs using the fragment-based approach. Herein, using ligand- and protein-observed fragment screening approaches, we identified niacin and hit 1 binding to the catalytic pocket of the main protease (M(pro)) of SARS-CoV-2, thereby modestly inhibiting the enzymatic activity of M(pro). We further searched for low-molecular-weight drugs containing niacin or hit 1 pharmacophores with enhanced inhibiting activity, e.g., carmofur, bendamustine, triclabendazole, emedastine, and omeprazole, in which omeprazole is the only one binding to the C-terminal domain of SARS-CoV-2 M(pro). Our study demonstrates that the fragment-based approach is a feasible strategy for identifying low-molecular-weight drugs against the SARS-CoV-2 and other potential targets lacking specific drugs.
  • |*Drug Repositioning[MESH]
  • |Antiviral Agents/*pharmacology[MESH]
  • |Betacoronavirus/*drug effects[MESH]
  • |Dose-Response Relationship, Drug[MESH]
  • |Models, Molecular[MESH]
  • |Molecular Weight[MESH]
  • |Peptide Hydrolases/chemistry/*metabolism[MESH]
  • |Protein Domains[MESH]
  • |SARS-CoV-2[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    7267 17.11 2020